Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.
   PubMed Web of Science ®Google Scholar
• Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.
   PubMed Web of Science ®Google Scholar
• Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–669.
   PubMed Web of Science ®Google Scholar
• Smolle MA, Bauernhofer T, Pummer K, et al. Current insights into long non-coding RNAs (LncRNAs) in prostate cancer. Int J Mol Sci. 2017;18(2):473.
   Web of Science ®Google Scholar
• Reicher A, Fosselteder J, Kwong LN, et al. Crosstalk between the Notch signaling pathway and long non-coding RNAs. Cancer Lett. 2018;420:91–96.
   PubMed Web of Science ®Google Scholar
• Gutschner T, Richtig G, Haemmerle M, et al. From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev. 2018;37(1):83–105.
   PubMed Web of Science ®Google Scholar
• Smolle MA, Pichler M. The role of long non-coding RNAs in osteosarcoma. Noncoding RNA. 2018;4(1):7.
   PubMedGoogle Scholar
• Del Vecchio F, Lee GH, Hawezi J, et al. Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk. Cancer Lett. 2018;421:94–102.
   PubMed Web of Science ®Google Scholar
• Schanza LM, Seles M, Stotz M, et al. MicroRNAs associated with Von Hippel-Lindau pathway in renal cell carcinoma: a comprehensive review. Int J Mol Sci. 2017;18(11):2495.
   PubMed Web of Science ®Google Scholar
• Chen H, Xu J, Hong J, et al. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. Mol Oncol. 2014;8(8):1393–1403.
   PubMed Web of Science ®Google Scholar
• Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. 2016;14(1):42–54.
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang DH, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–718.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Panzitt K, Tschernatsch MM, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330–342.
   PubMed Web of Science ®Google Scholar
• Kong D, Wang Y. Knockdown of lncRNA HULC inhibits proliferation, migration, invasion, and promotes apoptosis by sponging miR-122 in osteosarcoma. J Cell Biochem. 2018;119(1):1050–1061.
   PubMed Web of Science ®Google Scholar
• Sun XH, Yang LB, Geng XL, et al. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp Pathol. 2015;8(3):2994–3000.
   PubMed Web of Science ®Google Scholar
• Jiang X, Liu W. Long noncoding RNA highly upregulated in liver cancer activates p53-p21 pathway and promotes nasopharyngeal carcinoma cell growth. DNA Cell Biol. 2017;36(7):596–602.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Guo Q, Chen J, et al. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep. 2014;31(1):358–364.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song X, Wang X, et al. Silencing of LncRNA HULC enhances chemotherapy induced apoptosis in human gastric cancer. J Med Biochem. 2016;35(2):137–143.
   PubMed Web of Science ®Google Scholar
• Shi F, Xiao F, Ding P, et al. Long noncoding RNA highly up-regulated in liver cancer predicts unfavorable outcome and regulates metastasis by MMPs in triple-negative breast cancer. Arch Med Res. 2016;47(6):446–453.
   PubMed Web of Science ®Google Scholar
• Chen S, Wu DD, Sang XB, et al. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma. Cell Death Dis. 2017;8(10):e3118.
   PubMedGoogle Scholar
• Zhang Y, Li Z, Zhang Y, et al. Molecular mechanism of HEIH and HULC in the proliferation and invasion of hepatoma cells. Int J Clin Exp Med. 2015;8(8):12956–12962.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu YH, Chen X, et al. Effect of long non-coding RNA highly up-regulated in liver cancer (HULC) on the prognosis of cancer: a meta-analysis. Oncotarget. 2017;8(47):83246–83250.
   PubMedGoogle Scholar
• Sonohara F, Inokawa Y, Hayashi M, et al. Prognostic value of long non-coding RNA HULC and MALAT1 following the curative resection of hepatocellular carcinoma. Sci Rep. 2017;7(1):16142.
   PubMedGoogle Scholar
• Jiang Z, Liu H. Metformin inhibits tumorigenesis in HBV-induced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX. J Cell Biochem. 2018;119(6):4482–4495.
   PubMed Web of Science ®Google Scholar
• Wang YF, Zhang S, Li XQ, et al. Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival. Eur Rev Med Pharmacol Sci. 2016;20(19):3987–3991.
   PubMed Web of Science ®Google Scholar
• Peng W, Wu J, Feng J. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacothe. 2016;791:88–93.
   Google Scholar
• Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2(8):599–609.
   PubMed Web of Science ®Google Scholar
• Kong X, Qian X, Duan L, et al. microRNA-372 suppresses migration and invasion by targeting p65 in human prostate cancer cells. DNA Cell Biol. 2016;35(12):828–835.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366–5383.
   PubMed Web of Science ®Google Scholar
• Du Y, Kong G, You X, et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem. 2012;287(31):26302–26311.
   PubMed Web of Science ®Google Scholar
• Hammerle M, Gutschner T, Uckelmann H, et al. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology. 2013;58(5):1703–1712.
   PubMed Web of Science ®Google Scholar
• Muller S, Bley N, Glass M, et al. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018;46(12):6285–6303.
   PubMed Web of Science ®Google Scholar
• Kato T, Hayama S, Yamabuki T, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2007;13(2 Pt 1):434–442.
   PubMed Web of Science ®Google Scholar
• Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 2004;24(3):671–678.
   PubMed Web of Science ®Google Scholar
• Peduto L. ADAM9 as a potential target molecule in cancer. Curr Pharm Des. 2009;15(20):2282–2287.
   PubMed Web of Science ®Google Scholar
• Wan D, Shen S, Fu S, et al. miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC. Anticancer Agents Med Chem. 2016;16(4):414–423.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen F, Zhao M, et al. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem. 2017;292(37):15395–15407.
   PubMed Web of Science ®Google Scholar
• Fang C, Chen YX, Wu NY, et al. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 2017;7:40384.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lu G, Ke X, et al. miR-488 acts as a tumor suppressor gene in gastric cancer. Tumour Biol. 2016;37(7):8691–8698.
   PubMedGoogle Scholar
• Hu D, Shen D, Zhang M, et al. MiR-488 suppresses cell proliferation and invasion by targeting ADAM9 and lncRNA HULC in hepatocellular carcinoma. Am J Cancer Res. 2017;7(10):2070–2080.
   PubMed Web of Science ®Google Scholar
• He J, Zhang W, Zhou Q, et al. Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol. 2013;45(9):1962–1973.
   PubMed Web of Science ®Google Scholar
• Li F, Liu B, Gao Y, et al. Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett. 2014;588(4):538–544.
   PubMed Web of Science ®Google Scholar
• Lu Z, Xiao Z, Liu F, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget. 2016;7(1):241–254.
   PubMedGoogle Scholar
• Ou X, Lee MR, Huang X, et al. SIRT1 positively regulates autophagy and mitochondria function in embryonic stem cells under oxidative stress. Stem Cells. 2014;32(5):1183–1194.
   PubMed Web of Science ®Google Scholar
• Xiong H, Ni Z, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017;36(25):3528–3540.
   PubMed Web of Science ®Google Scholar
• Xin X, Wu M, Meng Q, et al. Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a. Mol Cancer. 2018;17(1):94.
   PubMed Web of Science ®Google Scholar
• Lin Z, Lu Y, Meng Q, et al. miR372 promotes progression of liver cancer cells by upregulating erbB-2 through enhancement of YB-1. Mol Ther Nucleic Acids. 2018;11:494–507.
   PubMedGoogle Scholar
• Li D, Liu X, Zhou J, et al. Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis. Hepatology. 2017;65(5):1612–1627.
   PubMed Web of Science ®Google Scholar
• Wu G, Wang Y, Lu X, et al. Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. BMC Cancer. 2015;15:182.
   PubMed Web of Science ®Google Scholar
• Wu G, Liu H, He H, et al. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer. 2014;14:107.
   PubMed Web of Science ®Google Scholar
• Gu H, Guo X, Zou L, et al. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;375(1–2):23–30.
   PubMed Web of Science ®Google Scholar
• Li SP, Xu HX, Yu Y, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget. 2016;7(27):42431–42446.
   PubMed Web of Science ®Google Scholar
• Dolan DW, Zupanic A, Nelson G, et al. Integrated stochastic model of DNA damage repair by non-homologous end joining and p53/p21-mediated early senescence signalling. PLoS Comput Biol. 2015;11(5):e1004246.
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 1995;377(6549):552–557.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–414.
   PubMed Web of Science ®Google Scholar
• Kim EM, Jung CH, Kim J, et al. The p53/p21 complex regulates cancer cell invasion and apoptosis by targeting Bcl-2 family proteins. Cancer Res. 2017;77(11):3092–3100.
   PubMed Web of Science ®Google Scholar
• Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014;31(12):346.
   PubMed Web of Science ®Google Scholar
• Zheng P, Li H, Xu P, et al. High lncRNA HULC expression is associated with poor prognosis and promotes tumor progression by regulating epithelial-mesenchymal transition in prostate cancer. Arch Med Sci. 2018;14(3):679–686.
   PubMed Web of Science ®Google Scholar
• Islam MA, Sooro MA, Zhang P. Autophagic regulation of p62 is critical for cancer therapy. Int J Mol Sci. 2018;19(5):1405.
   Web of Science ®Google Scholar
• Zhang L, Zou W. Inhibition of integrin beta1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway. Mol Med Rep. 2015;12(6):7869–7876.
   PubMed Web of Science ®Google Scholar
• Enomoto M, Tsuchida A, Miyazawa K, et al. Vitamin K2-induced cell growth inhibition via autophagy formation in cholangiocellular carcinoma cell lines. Int J Mol Med. 2007;20(6):801–808.
   PubMed Web of Science ®Google Scholar
• Lv Q, Hua F, Hu ZW. DEDD, a novel tumor repressor, reverses epithelial-mesenchymal transition by activating selective autophagy. Autophagy. 2012;8(11):1675–1676.
   PubMed Web of Science ®Google Scholar
• Sun T. Long noncoding RNAs act as regulators of autophagy in cancer. Pharmacol Res. 2018;129:151–155.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma W, Liu Y. Long non-coding RNA HULC promotes bladder cancer cells proliferation but inhibits apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway. Cancer Biomarkers. 2017;20(4):425–434.
   PubMed Web of Science ®Google Scholar
• Uzan VR, Lengert A, Boldrini E, et al. High expression of HULC is associated with poor prognosis in osteosarcoma patients. PLoS One. 2016;11(6):e0156774.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang J, Xu L, et al. Expression of HNF4G and its potential functions in lung cancer. Oncotarget. 2018;9(26):18018–18028.
   PubMedGoogle Scholar
• Sun H, Tian J, Xian W, et al. miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G. Dis Markers. 2015;2015:879254.
   PubMedGoogle Scholar
• Rao M, Zhu Y, Zhou Y, et al. MicroRNA-122 inhibits proliferation and invasion in gastric cancer by targeting CREB1. Am J Cancer Res. 2017;7(2):323–333.
   PubMed Web of Science ®Google Scholar
• Wang T, Gong X, Jiang R, et al. Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell. Am J Transl Res. 2016;8(2):968–980.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang Q, Zhou X, et al. Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-kappaB signaling pathway in vitro. Oncol Lett. 2016;12(5):3423–3428.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kaushik G, Subramaniam D, et al. Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol. 2017;10(1):10.
   PubMedGoogle Scholar
• Matouk IJ, Abbasi I, Hochberg A, et al. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol. 2009;21(6):688–692.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Huang CQ, Peng CW, et al. Long noncoding RNA HULC promotes colorectal carcinoma progression through epigenetically repressing NKD2 expression. Gene. 2016;592(1):172–178.
   PubMed Web of Science ®Google Scholar
• Dong Y, Cao B, Zhang M, et al. Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth. Oncotarget. 2015;6(26):22126–22138.
   PubMedGoogle Scholar
• Zhao S, Kurenbekova L, Gao Y, et al. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. 2015;34(39):5069–5079.
   PubMed Web of Science ®Google Scholar
• Yan H, Tian R, Zhang M, et al. High expression of long noncoding RNA HULC is a poor predictor of prognosis and regulates cell proliferation in glioma. Onco Targets Ther. 2017;10:113–120.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang X, Qi L, et al. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget. 2016;7(12):14429–14440.
   PubMedGoogle Scholar
• Rosen K, Shi W, Calabretta B, et al. Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand. A novel mechanism of anoikis of intestinal epithelial cells. J Biol Chem. 2002;277(48):46123–46130.
   PubMed Web of Science ®Google Scholar
• Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.
   PubMed Web of Science ®Google Scholar
• Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteomics Bioinf. 2017;15(2):59–72.
   PubMed Web of Science ®Google Scholar
• Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers. 2016;2016:9085195.
   PubMed Web of Science ®Google Scholar
• Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–8041.
   PubMed Web of Science ®Google Scholar
• Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget. 2014;5(22):11091–11102.
   PubMedGoogle Scholar
• Wu ZH, Wang XL, Tang HM, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32(1):395–402.
   PubMed Web of Science ®Google Scholar
• Svoboda M, Slyskova J, Schneiderova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014;35(7):1510–1515.
   PubMed Web of Science ®Google Scholar
• Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int. 2013;2013:136106.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Tang J, et al. HULC and Linc00152 act as novel biomarkers in predicting diagnosis of hepatocellular carcinoma. Cell Physiol Biochem. 2015;37(2):687–696.
   PubMed Web of Science ®Google Scholar
• Jin C, Shi W, Wang F, et al. Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget. 2016;7(32):51763–51772.
   PubMedGoogle Scholar
• Liu Y, Pan S, Liu L, et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS One. 2012;7(4):e35145.
   PubMed Web of Science ®Google Scholar
• Kang M, Sang Y, Gu H, et al. Long noncoding RNAs POLR2E rs3787016 C/T and HULC rs7763881 A/C polymorphisms are associated with decreased risk of esophageal cancer. Tumour Biol. 2015;36(8):6401–6408.
   PubMedGoogle Scholar
• Shaker OG, Senousy MA, Elbaz EM. Association of rs6983267 at 8q24, HULC rs7763881 polymorphisms and serum lncRNAs CCAT2 and HULC with colorectal cancer in Egyptian patients. Sci Rep. 2017;7(1):16246.
   PubMedGoogle Scholar
• Wang BG, Lv Z, Ding HX, et al. The association of lncRNA-HULC polymorphisms with hepatocellular cancer risk and prognosis. Gene. 2018;670:148–154.
   PubMed Web of Science ®Google Scholar
• Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017;474(24):4219–4251.
   PubMedGoogle Scholar
• Leuschner PJ, Ameres SL, Kueng S, et al. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep. 2006;7(3):314–320.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–1076.
   PubMed Web of Science ®Google Scholar
• Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–1625.
   PubMed Web of Science ®Google Scholar
• Prabhakar B, Zhong XB, Rasmussen TP. Exploiting long noncoding RNAs as pharmacological targets to modulate epigenetic diseases. Yale J Biol Med. 2017;90(1):73–86.
   PubMed Web of Science ®Google Scholar
• Gutschner T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–1189.
   PubMed Web of Science ®Google Scholar
• Pavco PA, Bouhana KS, Gallegos AM, et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res off J Am Assoc Cancer Res. 2000;6(5):2094–2103.
   PubMed Web of Science ®Google Scholar
• Parasramka MA, Maji S, Matsuda A, et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther. 2016;161:67–78.
   PubMed Web of Science ®Google Scholar
• Ozes AR, Wang Y, Zong X, et al. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017;7(1):894.
   PubMed Web of Science ®Google Scholar
• Pedram Fatemi R, Salah-Uddin S, Modarresi F, et al. Screening for small-molecule modulators of long noncoding RNA-protein interactions using alphascreen. J Biomol Screen. 2015;20(9):1132–1141.
   PubMedGoogle Scholar
• Sundaram P, Kurniawan H, Byrne ME, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013;48(1–2):259–271.
   PubMed Web of Science ®Google Scholar
• Vitiello M, Tuccoli A, Poliseno L. Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol. 2015;38(1):17–28.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar